Skip to content
Biodatica
Start free

Investigator

Jeff T Hutchins

INHALON BIOPHARMA, INC. · funded by NIAID

Companies
2

Resolved onto their grants.

Grants
5

Federal awards on file.

Non-dilutive funding
$4.7M

Summed across those awards.

First award
Jun 1, 2023

Latest Sep 1, 2025.

Companies from this work

Pre-ticker companies the crosswalk resolved onto a grant filed under this investigator. Momentum shows for the therapeutic areas your seat covers; open a dossier for the full crosswalk.

Grant record

Federal awards filed under this investigator name, newest first. Each links to the public record where the awarding agency publishes one.

  1. R44

    Development of IN-003PI as passive immunization against human metapneumovirus infection

    $1.0M

    Sep 1, 2025NIAIDINHALON BIOPHARMA, INC.NIH RePORTER · 11255384 (opens the source filing in a new tab)

  2. R44

    IND-enabling development for IN-005, an inhaled muco-trapping mAb therapy against Influenza A

    $1.0M

    Aug 1, 2025NIAIDINHALON BIOPHARMA, INC.NIH RePORTER · 11183972 (opens the source filing in a new tab)

  3. R44

    IND-enabling development for IN-003, an inhaled mAb therapy against human metapneumovirus infection

    $1.0M

    May 15, 2024NIAIDINHALON BIOPHARMA, INC.NIH RePORTER · 11089428 (opens the source filing in a new tab)

  4. R44

    SBIR: IND-enabling development of IN-007, an inhaled muco-trapping immunotherapy for COVID19 and other ACE2-targeted infections

    $1.0M

    Mar 1, 2024NIAIDINHALON BIOPHARMA, INC.NIH RePORTER · 11046650 (opens the source filing in a new tab)

  5. SB1

    GMP manufacturing and IND Filing of IN-002, a potent inhaled muco-trapping antibody therapy for Respiratory Syncytial Virus

    $609k

    Jun 1, 2023NIAIDINHALON BIOPHARMA, INC.NIH RePORTER · 11084445 (opens the source filing in a new tab)

This page aggregates public U.S. federal grant records filed under one investigator name and the companies Biodatica has resolved onto them. Names are shown as the awarding agency filed them; grant awards are non-dilutive federal funding, not equity or valuation. Distinct people who file under the same name would appear together here. It is informational only and not investment advice. Methodology · Data sources